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Abstract: Genome wide DNA alterations were evaluated by array CGH in addition to RNA expression proﬁ  ling in colorec-
tal cancer from patients with excellent and poor survival following primary operations.
DNA was used for CGH in BAC and cDNA arrays. Global RNA expression was determined by 44K arrays. DNA and 
RNA from tumor and normal colon were used from cancer patients grouped according to death, survival or Dukes A, B, C 
and D tumor stage. Conﬁ  rmed DNA alterations in all Dukes A – D were judged relevant for carcinogenesis, while changes 
in Dukes C and D only were regarded relevant for tumor progression.
Copy number gain was more common than loss in tumor tissue (p   0.01). Major tumor DNA alterations occurred in 
chromosome 8, 13, 18 and 20, where short survival included gain in 8q and loss in 8p. Copy number gains related to tumor 
progression were most common on chromosome 7, 8, 19, 20, while corresponding major losses appeared in chromosome 8. 
Losses at chromosome 18 occurred in all Dukes stages. Normal colon tissue from cancer patients displayed gains in chro-
mosome 19 and 20. Mathematical Vector analysis implied a number of BAC-clones in tumor DNA with genes of potential 
importance for death or survival.
The genomic variation in colorectal cancer cells is tremendous and emphasizes that BAC array CGH is presently more 
powerful than available statistical models to discriminate DNA sequence information related to outcome. Present results 
suggest that a majority of DNA alterations observed in colorectal cancer are secondary to tumor progression. Therefore, it 
would require an immense work to distinguish primary from secondary DNA alterations behind colorectal cancer.
Keywords: Colorectal cancer array CGH, Tumor DNA
Introduction
It is assumed that colorectal cancer development constitutes an evolutionary process and a stepwise 
accumulation of required genetic alterations leading to increased malignancy (Fearon and Vogelstein, 
1990). Around 15% of colorectal tumors are characterized by microsatellite instability (MSI or MIN) 
in combination with various mutations due to deﬁ  cient DNA mismatch repair (MMR) genes (Kinzler 
and Vogelstein, 1996). The majority of malignant colorectal tumors are however characterized by 
chromosomal instability (CIN) which refers to the appearance of gross chromosomal aberrations 
including gain and loss of large DNA regions or even whole chromosomes (Lengauer et al. 1998; 
Rajagopalan et al. 2003). CIN leads to increased inability to maintain genome integrity, although 
the precise order of genomic events is less deﬁ  ned. Opposite to CIN tumors, MSI neoplasms typi-
cally retain a near-diploic karyotype and show near normal frequencies of gross-chromosomal 
aberrations (Bhattacharyya et al. 1994; Parsons et al. 1993; Eshleman et al. 1998). However, aneu-
ploid changes typical for CIN tumors may occur early in low graded dysplastic adenomas, and are 
therefore proposed as major factors behind progression of colon cancer (Hermsen et al. 2002), 
although recent observations have questioned whether genetic instability precedes tumor formation 
(Cardoso et al. 2007). The development of advanced techniques such as high-resolution microarrays 
(Pinkel et al. 1998; Pollack et al. 1999; Snijders et al. 2001; Ishkanian et al. 2004) provides 342
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possibilities for a variety of detailed genome-
wide screening of DNA copy number changes in 
malignant tumors as well as epipenetic alterations 
(Pinkel and Albertson, 2005; Cardoso et al. 
2007). Seen together appearing results reveal an 
unexpected magnitude and complexity of genetic 
damage in both coding and non-coding regions, 
in various stages of colorectal cancer (Douglas 
et al. 2004; Nakao et al. 2004; Buffart et al. 2005; 
Mehta et al. 2005; Jones et al. 2005; Camps et al. 
2006). In the present study, we describe quantita-
tive DNA alterations by array CGH analysis in 
macrodissected colorectal cancer tissue as related 
to disease stage and survival following primary 
operations aimed for cure. Our results add to 
published information particularly on the differ-
ence of DNA alterations in tumors from patients 
with early relapse and death compared to cured 
patients.
Materials and Methods
Patient groups
The patient material comprised 64 patients 
operated on for sporadic primary colorectal 
carcinoma. Thirty-two patients who underwent 
primary surgery in Uppsala county, Sweden 
between 1988–1990 were subdivided into two 
groups according to survival. Nineteen patients 
alive 200 months after primary surgery were 
grouped as “alive.” Thirteen patients who died 
because of colorectal cancer within 12 months 
after their primary operation were grouped as 
“dead.” Alive patients comprised 6 males and 13 
females classiﬁ  ed as 4 Dukes A, 11 Dukes B, and 
4 Dukes C; 21% had MSI positive tumors and 
53% had tumors with p53 mutations. Dead 
patients comprised 7 males and 6 females classi-
ﬁ  ed as 3 Dukes B, 3 Dukes C and 7 Dukes D; 
31% had MSI positive tumors and 62% had 
tumors with p53 mutations as described elsewhere 
(Lagerstedt et al. 2005).
Additional 32 patients were included following 
primary operations in Uddevalla County of 
Sweden between 2001–2003 and were grouped 
according to tumor stage by the Dukes A–D clas-
siﬁ  cation. Each category of Dukes A, B, C and D 
comprised 8 patients with 4 males and 4 females, 
except the Dukes D group, which contained 5 
males and 3 females. None of the 64 patients 
underwent any additional treatment beside surgery 
according to our institutional standard procedures 
at the time of operation.
BAC array construction 
and procedures
Microarrays with complete genome coverage were 
produced from the 32K BAC clone library (CHORI 
BACPAC Resources, http://bacpac.chori.org/
genomicRearrays.php) by the Swegene DNA 
Microarray Resource Center, Department of 
Oncology, Lund University, Sweden (http://
swegene.onk.lu.se). DOP-PCR products were 
obtained from BAC DNA template and puriﬁ  ed 
using filter based 96-wells (PALL), dried and 
re-suspended in 50% DMSO. Arrays were printed 
on UltraGAPS slides (Corning) using a MicroGrid 
II spotter (Biorobotics) as described in details 
elsewhere (Jonsson et al. 2005a). BAC clones were 
mapped according to the Human May 2004 
Genome freeze (UCSC Genome Bioinformatics, 
http://www.genome.ucsc.edu).
Six 32K tiling BAC arrays were used to deter-
mine DNA copy number alterations in pooled 
tumor DNA from patients grouped as dead, alive, 
Dukes A, B, C and D in comparison to reference 
DNA (Human Genomic DNA from whole blood, 
Clontech, BD Biosciences). Array was run on 
tumor DNA from dead patients versus tumor DNA 
from alive patients. Normal colon tissue DNA from 
dead and alive patients was also hybridized against 
reference DNA. cDNA array analyses of DNA 
were also used to compare with observations found 
in BAC array analyses (Fig. 4).
Overall chromosomal aberrations were given 
as the number of BAC clones considered altered 
(gain or loss of copy number) divided by the total 
number of clones in the genome wide evaluation 
where X and Y-chromosomes were excluded.
DNA was extracted from fresh frozen primary 
colorectal carcinomas and normal colon tissue 
(down to serosa layer) with Qiamp DNA Mini kit 
(Qiagen) according to instructions. All tumors 
contained around 60–80% neoplastic cells accord-
ing to separate estimates, with remaining 20%–40% 
containing endothelial, stromal and inﬂ  ammatory 
cells. Sample labeling and hybridization were per-
formed as described (Jonsson et al. 2005a). Brieﬂ  y, 
1.5–3 μg genomic DNA from patients and reference 
DNA was differentially labeled with Cy5-dCTP or 
with Cy3-dCTP (Amersham Biosciences) using 
random primer labeling (Bioprime array CGH 343
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genomic Labeling module, Invitrogen). Labeled 
sample and reference DNA were mixed and unin-
corporated nucleotides were removed using 
CYScribe GFX puriﬁ  cation kit (Amersham Biosci-
ences) prior to coprecipitation with human Cot-1 
DNA. The labeling reactions were applied to arrays 
and incubated for 72 h at 37 °C. Slides were washed 
and scanned in Agilent microarray scanner (Agilent 
Technologies). Identiﬁ  cation of individual spots on 
scanned arrays was performed with GenePix Pro 
4.0 (Axon Instruments).
cDNA array construction
and procedures
cDNA microarrays containing 27,648 sequence-
veriﬁ  ed IMAGE clones from the Research Genet-
ics IMAGE clone library were obtained from the 
Swegene DNA Microarray Resource Center at 
Lund University (http://swegene.onk.lu.se). 6 μg 
of sample and reference DNA were labeled and 
hybridized according to previously described pro-
cedures for BAC arrays except that cDNA arrays 
were hybridized at 42 °C.
RNA extraction and microarray 
expression
Tumor and normal colon tissue RNA was either 
extracted with TRIzol reagent (Invitrogen Life 
Technologies). mRNA was linearly ampliﬁ  ed with 
BD smart mRNA ampliﬁ  cation kit (BD Biosciences, 
Clontech, Palo Alto, CA, U.S.A.), or extracted with 
Rneasy Fibrous Tissue Kit (Qiagen) where mRNA 
was selected with mRNA Puriﬁ  cation Kit (Amer-
sham Biosciences). RNA fractions were quality 
controlled in a Bioanalyzer (Agilent Technologies) 
and quantiﬁ  ed by a NanoDrop ND-1000A Spectro-
photometer (NanoDrop Technologies Inc). 400 ng 
polyA + mRNA from tumor and normal colon were 
labeled with Cy3-dCTP and Cy5-dCTP respectively 
(Amersham Biosciences) with Agilent Fluorescent 
Direct Label Kit and samples were hybridized to 
44K Human Whole Genome Oligo Microarrays 
(Agilent Technologies) using the In situ Hybridiza-
tion Kit Plus (Agilent Technologies), incubated at 
60 °C for 18 hours and scanned on an Agilent Micro-
array scanner. Three patients were hybridized indi-
vidually (with technical replicates, dye-swaps) and 
six patients were pooled and run as a single experi-
ment. Data were processed in Feature Extraction 
Software, v.7.5 (FE) (Agilent Technologies), back-
ground was subtracted, outliers ﬂ  agged and dyes 
were normalized with linear and lowess. Processed 
signals from FE output ﬁ  les were imported into 
GeneSpring Software, v.7.2 (Silicon Genetics, Agi-
lent Technologies) with Agilent Feature Extraction 
plug-in. Dye-transformation of speciﬁ  ed samples, 
normalizations per spot/divided by control channel 
as well as per chip/normalized to 50th percentile 
and ﬁ  ltering on ﬂ  ags were performed. Processed 
data from three individual patients and a pool of six 
patients were combined and the 99% conﬁ  dence 
interval was calculated from merged data to identify 
genes with aberrant expression. Patient data repre-
sent gene expression in tumors from Dukes A (1), 
Dukes B (2), Dukes C (4) and Dukes D (2) from 
ﬁ  ve females and four males.
DNA image analysis, data processing 
and statistics
Images were quantiﬁ  ed on an Agilent G2565AA 
microarray scanner (Agilent Technologies, Palo Alto, 
CA). Fluorescence intensities were extracted using 
the Genepix Pro 4.0 software (Axon Instruments Inc, 
Foster City, CA) uploaded into Bio Array Software 
Environment (BASE) open source software (http://
base.thep.lu.se) for further analysis (Saal et al. 2002). 
Data analysis was performed in BASE as described 
(Jonsson et al. 2005b). Brieﬂ  y, intensity ratios for 
each spot were obtained by calculating background 
corrected Cy3 and Cy5 intensities from the median 
and local background pixels. Spots with Cy3 and 
Cy5 intensities  65000 and a signal to noise ratio 
 1.5 and a spot radius  40 were excluded from the 
data set in BAC analyses, while cDNA ratios in spots 
were handled similarly without any restriction in 
signal intensities. Spots indicated as ﬂ  ags by the 
Genepix software were removed prior to normaliza-
tion by the Lowess curve ﬁ  t method for both plat-
forms (Yang et al. 2002). A moving average of three 
clones was applied and BASE implementation of 
CGH Plotter was used to determine deletion/ampli-
con boundaries (Autio et al. 2003). Noise constant 
was set to 15 and ampliﬁ  cation/deletion limits was 
set to log(2) values of ±0.2. High reproducibility 
considering log(2) values was obtained for all BAC 
clones within the 32K array with a mean SD of 0.135 
in self versus self hybridizations. Further, analysis 
of cells with different numbers of X-chromosomes, 
demonstrated a linear rise in log(2) values for 
X-clones (unpublished). Mapping information was 
retrieved from the USCS Genome Browser (March 
2005 freeze). The uniformity of log(2) ratio 344
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distribution in chromosomes as well as complete 
data sets were tested and conﬁ  rmed by the Kolmogo-
rov-Smirnoff test. Only autosomal clones were 
included in the analysis. The SD calculated from 
log(2) ratios from all samples was 0.14. Differences 
between samples were analyzed with χ
2-test and 
corrected by Bonferroni statistical adjustments.
Vector analysis was performed on data from 
hybridization of tumor DNA from dead and alive 
patients vs reference DNA from normal subjects. 
Net alterations in hybridization log(2) ratios were 
graphed in a two-dimensional coordinate system, 
where the different quadrants conﬁ  rm conditions 
or events that promote death or alive events directly 
or indirectly related to genetic deviations compared 
to normal reference DNA.
Results
Genome wide alterations in tumor 
tissue vs normal colon tissue
The number of aberrant clones ranged from 1–15% 
(genome wide) to 82% for individual chromosomes 
in tumor DNA (Table 1). Copy number gains were 
signiﬁ  cantly more common than loss of DNA 
sequences (p   0.01). Structural DNA alterations 
in tumor tissue versus normal DNA were found in 
each chromosome. Chromosomes with the highest 
prevalence of altered BAC clones were 8, 13, 18 
and 20 and least altered chromosomes were 1, 2, 
3, 5, 6 and 11. The size of copy number loss ranged 
from 4 to 351 BAC clones corresponding to 210 
kbp to 36 Mbp. The extent of gains and ampliﬁ  ca-
tions ranged from 2 to 599 BAC clones, corre-
sponding to 27 kbp to 55 Mbp. No incidence of 
homozygous deletions was observed.
RNA expression proﬁ  les in tumor tissue from 
colorectal cancer patients of the same cohort dis-
played 78 genes with significantly increased 
expression and 140 genes with decreased expres-
sion in tumor tissue vs normal colon tissue. Figure. 
1D shows the spectrum of expression along the 
genome compared to observed structural DNA 
alterations (Figs. 1A–C).
Genome wide DNA alterations in 
tumor tissue from dead and alive 
patients
Four percent, 8% and 2% of the BAC-clones of 
autosomal chromosomes were altered in tumor 
DNA analyzed from various sets of hybridization; 
(dead/alive, dead/reference, alive/reference) 
(Table 1). Copy number gain was more common 
than loss (p   0.01) and dead patients had a higher 
frequency of genome wide gain and loss in tumor 
DNA than alive patients (p   0.01). Several chro-
mosomes showed major DNA alterations, namely 
chromosomes 8, 13, 18 and 20 in tumor tissue 
(Table 1, Fig. 2).
Copy number changes in tumor DNA 
from dead vs alive patients
Tumor DNA vs tumor DNA
Gain was found for 63% of the clones covering 
chromosome 8 starting at the 8p-arm (6.3 Mb at 
8p11.21–8p11.1) and covering 92% of the q-arm 
(Table 2). A 17 Mb region on chromosome 9 (9q33.2–
9q34.3) and a 9 Mb region on chromosome 13 
(13q12.12–13q13.1) were gained, which represented 
15% and 8% of all clones covering respective chro-
mosome (Fig. 1, Table 2). A major loss was observed 
at 8p21.3–8p12 (Table 2).
Tumor DNA vs reference DNA
Sixty-seven percent of the clones covering chromo-
some 8 were gained in tumor DNA from dead 
patients with start at the 8p-arm (6.3 Mb at 
8p11.21–11.1) covering 97% of the q-arm (Fig. 2). 
Likewise, 61% of BAC-clones in chromosome 13 
were gained in tumor DNA from dead patients. 
Three restricted regions were found at 
13q11–13q14.2 (35 Mb), 13q21.33–13q31.1 
(9 Mb) and 13q31.3–13q33.1 (9 Mb) (Fig. 2). Loss 
of DNA at 8p occurred in tumor DNA from dead 
patients, where a 22 Mb deletion started at 8p23.3–
8p21.3. Three regions with copy number loss in 
chromosome 18 were found in dead patients cor-
responding to 25% of the BAC-clones (3 Mb start-
ing at 18p11.21, 6 Mb at 18q11.1–18q12.1 and 9 
Mb starting at 18q21.33–18q22.3) (Fig. 2).
DNA alterations related to tumor
progression (Dukes A + B, C + D)
Seven percent, 4%, 15% and 12% of BAC-clones 
representing autosomal chromosomes were altered 
in Dukes A, B, C and D tumors respectively 
(Table 1). Copy number gain was signiﬁ  cantly 
more common than copy number loss in all Dukes 
stages (p   0.01). Gains were found in chromosome 
7 (9%–45%), 8 (1%–55%) and 20 (46%–76%) in 345
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Dukes A–D (Table 2). Copy number loss was 
observed in 6%–61% of all BAC-clones represent-
ing chromosome 18 in all Dukes classes (Fig. 2).
Copy number changes in Dukes A + B 
and Dukes C + D
Tumor DNA from Dukes C + D displayed addi-
tional gains in chromosome 7, 8, 19 and 20 com-
pared to Dukes A + B. Major loss of DNA 
sequences in chromosome 18 was similar between 
Dukes A + B and C + D while chromosome 8 
showed major loss in Dukes C + D not observed 
in Dukes A + B (Table 2). Candidate genes related 
to tumor progression in control of cell proliferation 
and apoptosis are shown in Table 4 and 5.
Normal colon tissue DNA from cancer patients 
displayed gain in chromosome 19 and 20 compared 
to normal reference DNA (Table 2).
Large-scale copy number variation in 
normal colon tissue DNA
Conﬁ  rmed and unconﬁ  rmed large-scale copy num-
ber variaton was observed in normal colon tissue 
from cancer patients with different clinical outcome 
(Iafrate et al. 2004; Sebat et al. 2004; Eichler, 
2006). These changes are summarized in Table 3. 
Alive patients displayed only conﬁ  rmed CNV locus 
while both confirmed and unconfirmed DNA 
alterations occurred in our dead patients. Such 
unconﬁ  rmed DNA locus were evaluated for candi-
date genes with importance for tumor progression 
according to proliferation or apoptosis (Table 6).
Vector analysis
Figure 5 demonstrates distributions of DNA altera-
tions between dead and alive patients in whole 
genome hybridizations versus normal reference 
DNA. Each observation indicates its proportional 
weight in vectors moving either towards death or 
survival. According to this plot, we ranked the 20 
most extreme BAC-clones contributing to death 
events due to copy number gain or loss. Genes in 
these DNA regions represent candidates related to 
disease speciﬁ  c mortality as presented in Table 7.
Discussion
The present study evaluates structural (sequence) 
alterations in DNA isolated from tumor tissue 
obtained at primary curative resections of 
Figure 1. Genome wide array CGH BAC analysis.Tumor DNA from 
dead patients was hybridized against tumor DNA from alive patients 
(A); tumor DNA from dead patients vs normal reference DNA (B); 
tumor DNA from alive patients vs normal reference DNA (C). Relative 
chromosomal copy number is given on the y-axis as the log(2) ratio. 
Each ratio represents a BAC clone on the array. Values of log(2) 
ratios above 0.2 were regarded gain of copy number and log(2)ratios 
below −0.2 were considered loss of copy number. Alive patients were 
cured from colorectal cancer with more than 10 years survival, while 
dead patients did not survive beyond 1 year following their primary 
operation. a) is the ± 0.2 log(2) ratio (∼95% confidence limit) 
determined by CGH plotter analysis software. Panel D shows RNA 
expression in tumor tissue vs normal colon tissue RNA from a 
comparable group of 9 cancer patients (Dukes A – D) selected by 
chance from the main patient cohort. b) represents ±2.6SD 
(99% conﬁ  dence interval).
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Figure 2. Results from 9 array based CGH analyses on chromosome 
8, 13, 18 and 20 in tumor DNA (TT) and normal colon tissue DNA 
(NT). Green bars represent loss of copy number and red represents 
gain of copy number. Gray is DNA sequences without statistically 
signiﬁ  cantly structural genomic alterations.
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Figure 3. Genome wide array CGH analyses where tumor DNA from 
patients with colorectal cancer staged as Dukes A, B, C and D 
respectively was hybridized vs normal reference DNA as described 
in Methods. 349
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Table 3. Large Scale Copy Number Variation in DNA from normal colon mucosa in dead and alive patients at 
the time of curative operation for colorectal cancer.
  Normal mucosa DNA from dead   Normal mucosa DNA from alive 
  patients vs reference DNA    patients vs reference DNA  
Chromosome    
   Conﬁ  rmed CNP  Unconﬁ  rmed   Conﬁ  rmed CNP  Unconﬁ  rmed CNP
   locus  CNP locus   locus  locus 
1     -  -  -
2 2p16.1
f -  -  -
3 3p23
h   - -
4   4p15.32
b -  4p13
g -
5 5q13
a  - -  -
6 6q11.1
a, 6q27
h,i     - -
7 7q11.21
a, 7q11.23
j   -  -
8   -  -  8q21.1
a -
9 -  - 9p24.3
a -
10 10q11.23
k   -  -
11   10q23.1
j     -  -
12   -  -  -  -
13   -  -  -  -
14   14q11.2
a,b, 14q31.3
h 14q11.1  -  -
15   15q15.1
d -  15q11.2
e -
16 -  -  16p11.2
a -
17 17p13.2
j   -  -
18   -  18q11.2   -  -
19   19p13.3
e -  -  -
20   20p11.1
a,20q13.33
c -  20q13.33
c -
21   -  -  21q22.3
a -
22       22q12.2
a 
   -  -  22q12.3
c -
aIafrate et al, Nat Genet. 2004, 36:949–951; 
bSebat et al, Science 2004, 305:525–528; 
cTuzun et al, Nat Genet. 2005, 37:727–732; 
dSharp 
et al, Am J Hum Genet. 2005, 77:78–88; 
eDe Vries et al, Am J Hum Genet. 2005, 77:606–616; 
fMc Carroll et al, Nat Genet. 2006, 38:86–92; 
gHinds et al, Nat Genet. 2006, 38:82–85; 
hRedon et al, Nature 2006, 444:444–54; 
iMills et al, Genome Res. 2006, 16:1182–90; 
jWong et al, 
Am J Hum Genet. 2007, 80:91–104; 
kLocke et al 2006, 79:275–90.
Table 4. Copy number gain and loss of genes related to cell proliferation and apoptosis in altered tumor DNA 
regions as deﬁ  ned in Table 2 from patients with short survival (dead patients). 
Copy number  Cytoband  Proliferation  Protein function   Apoptosis   Protein function
Change
Gain  8p11.21    ANK1   Involved in cell activation,
     proliferation   
 8q22.2        STK3  Activation  presumably
          allows cells to resist
        unfavorable  conditions
 8q24.21    V-MYC   Transcription factor   V-MYC  Multifunctional,  nuclear 
        phosphoprotein 
 8q24.22    WISP1   Belongs to connective
      tissue growth factor family   
 8q24.3    PTP4A3   Regulates cellular processes   
Loss  8p21.3−       TNFRSF10B Transduces  apoptosis
        signal 
 8p23.1    SOX7  Potential  transcriptional
     regulator  involved
      in tumorigenesis    
 8p22    CNOT7   Binds to antiproliferative
     protein     
 8p22    FGF20   Involved in cell growth350
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Table 6. Unconﬁ  rmed CNP locus and corresponding genes with known function in DNA from normal colon tissue 
obtained from dead patients of potential importance for interactions to predict death events.
Copy Number   Cytoband   Gene Name   Protein function   BAC clone
Change
Gain  18q11.2    GATA-6   Translation factor that may be  RP11-121I20–RP11-219C07
      important for regulating terminal
      differentiation and/or proliferation  
   CTAGE1  Cutaneous  T-cell  lymphoma-
     associated  antigen 
Loss  18q11.2    C18orf8   Colorectal Cancer associated  RP11-197B23–RP11-626P24
     protein  Mic-1
   LAMA3   Thought to be involved in cell
      adhesion and signal transduction
colorectal cancer. Several earlier studies have 
addressed relationships between DNA aberrations 
and disease progression, outcome and response to 
adjuvant treatment (De Angelis et al. 2001; Bardi 
et al. 2004; Diep et al. 2004; Chang et al. 2006; 
Diep et al. 2006). The traditional approach in such 
efforts is to investigate a number of patients with 
statistical power to relate genetic alteration to 
survival and treatment response. This approach, 
with genome wide analyses on material from indi-
vidual patients on large cohorts, is restricted by 
ﬁ  nancial costs and statistical aspects in microarray 
analyses. Therefore, we chose an alternative 
approach with analyses on pooled DNA prepared 
from individual patients grouped according to 
clinical outcome or tumor stage (Dukes A–D), 
which represents a more robust model with less by 
chance variation considering the large number of 
clones (∼32000) in each assay. Thus, a model based 
on pooled DNA and RNA provides more stabilized 
information by canceling out random variations as 
emphasized by Cardoso et al. (Cardoso et al. 2007). 
Patients with either poor or excellent survival fol-
lowing surgery were selected from a large cohort 
of patients with colorectal cancer selected by 
chance and subjected to standard treatment at our 
institution. In a group from all operated patients 
during 1990 and 2002 we randomly selected 13 
patients who died in colorectal cancer within 12 
months vs 19 patients who survived for more than 
ten years, which is statistically equal to be cured. 
A limitation in analyses on pooled DNA is that 
small but signiﬁ  cant structural alterations may be 
unidentiﬁ  ed and thereby decrease the sensitivity 
of analyses. However, as a screening procedure for 
evaluation of major factors, our approach is statis-
tically superior. In order to decrease the risk for 
misinterpretations in conclusion of results from 
dead vs alive patients we also conﬁ  rmed such 
results by hybridization of tumor DNA vs reference 
leucocyte DNA commercially available from 
healthy individuals. Given the existence of copy 
number variants of relatively high frequency in 
general population (Redon et al. 2006) it may not 
be beneﬁ  cial to analyze a deﬁ  ned “normal refer-
ence DNA.” However, this comparison is regarded 
on internal analytical standard being commercially 
available world wide.
DNA alterations detected in the surgically 
removed tumors represents the sum of changes 
accumulated during disease progression (Rajago-
palan et al. 2003; Michor et al. 2005). It is possible 
that certain alterations are critical for carcinogenesis 
while other may promote invasive growth and 
metastatic spread (Buffart et al. 2005; Mehta et al. 
2005; Ghadimi et al. 2003; Saha et al. 2001). Con-
siderable efforts have been devoted to delineate 
differences between early and late events in colorec-
tal cancer development. (Lengauer et al. 1998; 
Lengauer et al. 1997). Theoretically, it may well be 
that critical genetic events during carcinogenesis are 
less important for tumor progression and vise versa 
(Hunter, 2004). Here, we approached this concept 
by comparing DNA alterations in patients with 
tumors of well-deﬁ  ned clinical stage according to 
Dukes. Accordingly, patients with tumor stage of 
Dukes A and B have world wide clear cut better 
outcome compared to patients with Dukes C and D 
stage. Therefore, when a deﬁ  ned DNA alteration 
occurs in all Dukes A–D stages, and is not present 
in normal tissue, it should be related to carcinogen-
esis and early progression. On the other hand, when 
alterations appear in Dukes C and D tumors only, 
they should be associated with tumor progression.352
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In general, our study reveals that DNA copy 
number gains are more frequent than losses in 
colorectal cancer. Based on above principles we 
observed a number of alterations that distinguish 
tumors with excellent versus poor prognosis, most 
obvious being the alterations on chromosome 8. 
Figure 4. Copy number gain and loss in chromosome 8 based on 
three CGH arrays where tumor DNA from dead patients was hybrid-
ized either to DNA from alive patients or to reference DNA. (A: 32k 
BAC array; B: 27k cDNA array; C: 32k BAC array). The statistical 
conﬁ  dence interval was ±0.2 log(2) ratio.
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Loss of a limited region on 8p (8p23–8p21) 
occurred more often in patients of poor prognosis, 
whereas gain of a large proportion of chromosome 
8 (including most of 8q) characterized these 
tumors. Frequent DNA copy number gain at 
9q33.2–9q34.3 and 13q12.12–13q13.1 in tumors 
of poor prognosis may reveal the existence of 
activated oncogenes that confer aggressive disease. 
These tumors also contained frequent losses at 
three limited regions on chromosome 18, including 
two 18q regions that suggest the existence of 
important tumor suppressor genes. However, copy 
number loss on chromosome 18 was seen in both 
Dukes A + B and C + D tumors, suggesting that 
these are early events in colorectal tumor develop-
ment. Contrary, Dukes C + D tumors displayed 
gains on chromosome 7, 8, 19 and 20 in compari-
son with Dukes A + B tumors, supposedly related 
to tumor progression. Losses on chromosome 8p 
where observed in Dukes C + D but not in Dukes 
A + B. Unexpectedly, it was observed that normal 
colon tissue harbored quantitative DNA alterations 
(gains at chromosome 19 and 20) also found in 
Dukes C + D tumors, which contradict their con-
nection to tumor progression. These DNA altera-
tions may reﬂ  ect the toxic environment that colon 
epithelial is exposed to during life-time predispos-
ing to carcinogenesis, but it may also represent 
CNVs among different subject populations.
Several studies have implied critical DNA 
alterations that predict clinical outcome. Many such 
reports have been evaluated in less complex exper-
imental models as cultured tumor cells, where 
signal transduction pathways in control of cell 
proliferation and apoptosis are well described. 
However, overall genomic aberrations observed in 
the present material appear a major challenge to 
distinguish primary from secondary DNA altera-
tions. The regions deﬁ  ned here (e.g. on chromo-
some 8) include several hundred of altered genes 
that may co-variate with other disease speciﬁ  c 
alterations without having any primary cause-effect 
relationship on either carcinogenesis or progression. 
A hint to this perspective may be to compare struc-
tural DNA alterations to signiﬁ  cant altered RNA 
expression along the genome which provide infor-
mation on DNA alterations in expressed genes 
(Pollack et al. 2002). Accordingly, Pollack et al. 
estimated that approximately 12% of variations in 
gene expression in breast cancer could be attributed 
to underlying copy number changes. Corresponding 
rough estimates on the present material may be 353
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Figure 5. Distributions of log(2) in BAC-clone hybridizations of tumor DNA from dead and alive patients versus normal reference DNA as 
described in Methods. The upper left and lower right quadrants represent conditions where both non-surviving and surviving patients have 
pronounced and less pronounced DNA alterations compared to normal reference DNA. Thus, in the upper left quadrant the non-surviving 
patients have pronounced and surviving patients less pronounced DNA alterations compared to normal individuals. The lower right quadrant 
represents opposite conditions.
around 5% considering signiﬁ  cantly altered expres-
sion versus copy number changes in tumors. Deﬁ  -
nite information on altered expression versus copy 
number changes must await analyses on the RNA 
and DNA from the same tissue specimen (Cardoso 
et al. 2007), which is under way in our laboratory. 
Therefore, we used two dimensional vector analy-
sis to sort out the 20 most extreme alterations related 
to poor survival and found that a majority of these 
genomic regions (represented by BAC clones) 
contained only a few known genes that may be 
related to cancer progression. This dilemma would 
require more thorough comparisons with gene 
expression and functional studies and it is not 
resolved simply by adapting available models of 
bioinformatics on genomic data. Obviously, there 
is no simple solution to rank positive and negative 
factors in prediction of clinical outcome, since it 
will demand genome-wide analyses on several ten-
thousands of patients to resolve such predictions 
by classic statistics. The situation appears even 
more problematic considering redundant metabolic 
pathways to overcome established defects in the 
control of gene expression including epigenetic 
changes and micro RNAs (Feinberg et al. 2006; 
Michael et al. 2003). In this perspective it presently 
appears an impossible mission to resolve these 
questions by available models.354
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In conclusion, the results in the present study 
demonstrate that tiling array CGH is a powerful 
approach for genome-wide identiﬁ  cation of DNA 
copy number alterations in pooled DNA from 
cancer patients. We used pools of tumors from 
clinically and/or pathologically well-defined 
patient subgroups selected randomly to sort out 
only major genomic patterns related to carcino-
genesis, tumor progression and prognosis. 
Despite this approach our results demonstrate an 
enormous number of DNA sequences that may 
explain carcinogenesis, tumor growth progres-
sion and disease speciﬁ  c mortality. A next step 
should be to distinguish primary DNA events 
from secondary covariates to explain disease 
progression, although this presently seems an 
overwhelming task.
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Note
Genome array CGH analysis of colorectal cancer 
in relation to disease progression and global RNA 
expression.
Table 7. BAC-clones ranked by the greatest differences in log2 ratio between tumor DNA from dead and alive 
patients and genes of either interest
a or non-interest
b that map to corresponding regions. Gains and losses reﬂ  ect 
the aberration in DNA from dead patients when DNA from alive patients lacks the alteration or shows converted 
properties.
Copy Number  Cytoband   BAC clone   Gene Name   Protein function
Change
Gain   8q23.3   RP11-771F4   b  
  8q24.3   RP11-105P9   c  
  10p13   RP11-609G23   b 
  12p12.3   CTD-2009E21   b  
  8q24.13   RP11-532K12   HAS2   Produced during wound healing and tissue repair
        to provide a framework for ingrowth of blood
       vessels  and  ﬁ  broblasts 
  8q24.12   RP11-389M7   b 
  3q25.2   RP11-597G4   c  
  8q24.13   RP11-293H22   b  
  4q13.3   RP11-393B3   b  
  8q24.21   RP11-739G15   c  
Loss   1q23.1   RP11-769J1   CD1   T-cell surface glycoprotein, associates
        non-covalently with beta-2-microglobulin 
  5q31.3   RP11-614D16   b  
  11q12.2   RP11-565O16   PRPF19   Implicated in double-strand break repair 
     CD8   T-cell differentiation antigen 
 4q12  RP11-777P23    b  
 12q21.33  RP11-632B21    c  
  17q11.2   RP11-518B17   NF1   Negative regulator of the ras signal
       transduction  pathway 
 12q14.1  CTD-2260D13    b  
  10q22.3   RP11-732B12   c  
  11q14.3   RP11-715F05   b  
 22q11.21  RP1154C2    b  
aGene related to cell proliferation, apoptosis or cell cycle associated proteins.
bGenes without obvious interest for tumor progression.
cNo reported genes map to the region covered by this BAC-clone.355
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